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Parkway, Suite 200, Alpharetta, GA 30005, USARetinal gene therapy using adeno-associated viruses (AAVs) is
constrained by the mode of viral vector delivery. Intravitreal
AAV injections are impeded by the internal limiting mem-
brane barrier, while subretinal injections require invasive sur-
gery and produce a limited region of therapeutic effect. In this
study, we introduce a novel mode of ocular gene delivery in rhe-
sus macaques using transscleral microneedles to inject AAV8
into the subretinal or suprachoroidal space, a potential space
between the choroid and scleral wall of the eye. Using in vivo
imaging, we found that suprachoroidal AAV8 produces
diffuse, peripheral expression in retinal pigment epithelial
(RPE) cells, but it elicited local inﬁltration of inﬂammatory
cells. Transscleral subretinal injection of AAV8 using micro-
needles leads to focal gene expression with transduction of
RPE and photoreceptors, and minimal intraocular inﬂamma-
tion. In comparison, intravitreal AAV8 shows minimal trans-
duction of retinal cells, but elicits greater systemic humoral
immune responses. Our study introduces a novel mode of
transscleral viral delivery that can be performed without vitre-
oretinal surgery, with focal or diffuse transgene expression pat-
terns suitable for different applications. The decoupling of
local and systemic immune responses reveals important in-
sights into the immunological consequences of AAV delivery
to different ocular compartments surrounding the blood-
retinal barrier.Received 13 December 2019; accepted 6 January 2020;
https://doi.org/10.1016/j.omtm.2020.01.002.
Correspondence: Glenn Yiu, MD, PhD, Department of Ophthalmology & Vision
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The use of adeno-associated viral (AAV) vectors has been instru-
mental in the development of ocular gene therapies for treating in-
herited retinal diseases and complex degenerative retinal conditions.
AAVs are nonpathogenic, replication-deﬁcient, and exhibit low
immunogenicity. They also have the ability to infect different retinal
cell types, making them efﬁcient vectors for gene transfer in the eye.1
Recombinant AAV can encode a promoter and therapeutic trans-
gene cassette up to 4.7 kb ﬂanked by AAV inverted terminal repeats
for replication and packaging. Transduction efﬁciency and tissue
tropism are determined by the capsid,2 with hundreds of AAV var-
iants described to date.3,4 The ﬁrst US Food and Drug Administra-Molecular Therapy: Methods & C
This is an open access article under the CC BY-NC-tion (FDA)-approved gene therapy for the eye employs AAV2 to
express the RPE65 gene encoding a retinal isomerase to treat patients
with biallelic RPE65 mutation-associated retinal dystrophy, a rare
retinal condition characterized by severe visual impairment that be-
gins during infancy.5–10 Similar gene therapy strategies have also
been developed for retinitis pigmentosa,11–13 achromatopsia,14,15
X-linked retinoschisis,16,17 and neovascular forms of age-related
macular degeneration (AMD),18–20 with many ongoing clinical trials
underway.
Many current retinal gene therapy protocols employ subretinal injec-
tion of the AAV vector, which involves vitrectomy surgery and inser-
tion of a cannula through the retina to create a retinotomy to deliver
the viral particles to photoreceptors and/or underlying retinal
pigment epithelium (RPE). Compared to systemic delivery, AAV in
the subretinal space elicits a reduced immune response compared
to systemic delivery, similar to the anterior chamber-associated im-
mune deviation (ACAID) that enables corneal transplantation
without immunosuppression.21,22 However, the technique is more
difﬁcult and subject to potential complications of vitrectomy surgery
such as retinal tear, retinal detachment, the need for more eye surgery,
cataract, intraocular pressure abnormalities, and intraocular infec-
tion.23,24 The focal injection of AAV particles also limits the therapeu-
tic effect to a small region near the injection site. Furthermore,
because these subretinal injections must be performed in an operating
room with a surgical microscope, access is costly for patients and
repeated treatments are difﬁcult.
Intravitreal injections can overcome some of the limitations of sub-
retinal delivery, and they are frequently performed in ofﬁce settings
by ophthalmologists to deliver anti-angiogenesis agents for treatinglinical Development Vol. 16 March 2020 ª 2020 The Author(s). 179
ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Molecular Therapy: Methods & Clinical Developmentneovascular retinal conditions.25 However, the internal limiting
membrane (ILM) limits the penetration of the current generation
of AAV vectors, and transduction is often limited to inner retinal
layers.26 Although surgical removal of the ILM can enhance AAV
transduction from the vitreous,27,28 vitrectomy is necessary for this
procedure. Novel AAV variants identiﬁed by in vivo-directed
evolution29 or mutation of capsid tyrosines30 may also improve
transduction of the outer retina, but efﬁcacy in murine eyes does
not reliably predict effectiveness in primates. Also, intravitreal
AAV causes more intraocular inﬂammation and elicits a more
potent humoral immune response than does subretinal administra-
tion.31–34
The suprachoroidal space is the potential space located between the
choroidal vasculature and the scleral wall of the eye. In humans,
this layer is rarely detectable except in pathologic conditions when
accumulation of suprachoroidal ﬂuid becomes visible on ultrasonog-
raphy,35 although advances in spectral domain-optical coherence to-
mography (SD-OCT) allow the space to be visualized in some healthy
eyes also.36,37 Suprachoroidal delivery of pharmacologic agents has
been explored for targeted delivery to chorioretinal tissues with
improved pharmacokinetics and duration.38 Suprachoroidal delivery
can be achieved by surgical cannulation39 or transscleral micronee-
dles40,41 that are only long enough to penetrate the sclera without
perforating the retina (Figure 1A). In clinical studies, suprachoroidal
injection of triamcinolone acetonide suspension using microneedles
showed efﬁcacy in treating noninfectious uveitis and retinal vein
occlusions.42,43
In this study, we report the novel use of transscleral microneedles
to deliver AAV vectors to the subretinal or suprachoroidal space
using a nonhuman primate model. While common laboratory ro-
dents have a large lens relative to the size of the eye, a thin sclera,
and ocular dimensions that are too small for reliably accessing the
suprachoroidal space, rhesus macaques have ocular dimensions
and vascular architecture that are nearly identical to humans.44,45
Using AAV8, which has been shown to effectively transduce
photoreceptors and RPE,46 we found that suprachoroidal AAV8
delivery produced diffuse, peripheral transduction of mostly
RPE, while subretinal injection using transscleral microneedles
led to a robust, but localized area of gene transfer to multiple
retinal cell types. Without systemic immunosuppression, supra-
choroidal AAV8 also elicited local inﬁltration of inﬂammatory
cells in the outer retina and choroid, but less vitreous inﬂamma-
tion or systemic humoral immune responses. Our results demon-
strate distinct expression patterns of subretinal and suprachoroidal
AAV delivery using transscleral microneedles that may be suitable
for different potential applications of retinal gene therapy, and
they highlight the immune consequences of AAV exposure to
different ocular compartments bordering the blood-retinal barrier
(BRB). These ﬁndings suggest that suprachoroidal AAV injections
may be a promising, novel route for ocular gene delivery, if the po-
tential immune complications of this technique can be adequately
addressed.180 Molecular Therapy: Methods & Clinical Development Vol. 16 MarchRESULTS
Suprachoroidal AAV8 Transduction Is Diffuse, Peripheral, and
Circumferential
We screened 24 rhesus macaques (4–10 years of age) for absence of
pre-existing serum neutralizing antibodies (NAbs) to AAV8 using
an in vitro transduction inhibition assay,47 and identiﬁed 6 animals
(mean age, 8.3 ± 2.4 years; 3 males/3 females) with no detectable
NAbs (<1:2,560), consistent with the high prevalence of anti-AAV8
NAbs reported in rhesus macaques.48 We injected both eyes of three
of these animals with nonhuman primate-grade AAV8 expressing
enhanced green ﬂuorescent protein (GFP) under a ubiquitous cyto-
megalovirus (CMV) promoter at two different doses (7  1011 or
7 1012 vector genomes [vg]/eye) using a 700-mm-long 30-gauge mi-
croneedle (Figure 1B, Clearside Biomedical, Alpharetta, GA, USA) in-
serted through the conjunctiva and sclera into the suprachoroidal
space in the superotemporal quadrant (single 100-mL injection) of
left eyes, and both superotemporal and inferonasal quadrants (two
50-mL injections) of right eyes (Figure 1C). No surgical microscope
or vitrectomy surgery was required. Animals were scheduled for
in vivo ﬂuorescence retinal imaging by scanning laser ophthalmos-
copy (SLO) to measure GFP expression at 1 week, 1 month, and
3 months after AAV8 injection, followed by necropsy for histological
analysis (Figure 1D). One of these animals (rhesus 00) was subse-
quently found to have existing NAbs and erroneously enrolled, and
was excluded from further analyses. While the animal that received
the lower dose (rhesus 01) showed no detectable expression at any
time points, the animal injected with 7  1012 vg/eye (rhesus 02) ex-
hibited scattered areas of punctate GFP ﬂuorescence bilaterally in the
peripheral fundus at 1 week (Figures 1E and 1H), which increased at
1 month (Figures 1F and 1I), but was not detectable at 3 months (Fig-
ures 1G and 1J). Although the facial contour of rhesus monkeys limits
our steering of the SLO device to image some quadrants of the periph-
eral retina, GFP expression was near circumferential, with no predi-
lection for the injection location or quadrant. These results suggest
that suprachoroidal delivery of AAV8 results in diffuse and peripheral
expression of the GFP transgene, although durability may be limited.Comparison of Suprachoroidal, Subretinal, and Intravitreal AAV8
Transduction In Vivo
Based on results from these dose-ranging studies and given the pe-
ripheral pattern of expression, we adjusted our protocol to transscler-
ally inject more posteriorly at 10 mm posterior to the limbus (near the
globe equator) using the microneedles, and inject one animal intravi-
treally for comparison using a standard 0.5-inch-long 30-gauge nee-
dle through the pars plana at 4 mm posterior to the limbus (Fig-
ure 1B). We also scheduled these animals to undergo necropsy
earlier at months 1 and 2 after injection due to the GFP expression
loss at month 3 (Figure 1D). Interestingly, we found that transscleral
microneedle injections at this posterior location achieved subretinal
AAV delivery in two eyes, as evidenced by a small spot of subretinal
hemorrhage seen on funduscopic examination. Compared with
suprachoroidal AAV8 (Figures 2A and 2D), subretinal delivery of
AAV8 using this transscleral approach produced robust focal2020
Figure 1. Experimental Design and In Vivo GFP Transgene Expression in Rhesus Macaque Eyes after Suprachoroidal Injection of AAV8
(A) Diagram of a primate eye showing different modes of AAV delivery, including intravitreal, subretinal (transretinal), and suprachoroidal or subretinal injections using
transscleral microneedles. (B) Photograph comparing a standard 30-gauge needle with the transscleral microneedle used in this study. (C) Table outlining study animals and
eyes, demographics, AAV8 dose, location and quadrant of injections, and the anatomic location of the injectant. *Rhesus 00 was found to have pre-existing AAV-neutralizing
antibodies and was subsequently excluded. (D) Schematic of time points for ocular imaging and necropsy of study animals. (E–G) Scanning laser ophthalmoscopy (SLO)
montages and (H–J) magnified views of the yellow-dashed boxes in (E–G) showing GFP expression at 1 week (E and H), 1 month (F and I), and 3 months (G and J) after AAV
injections. Scale bars, 1 mm. F, female; M, male; OD, right eye; OS, left eye; IN, inferonasal; IVT, intravitreal; SC, suprachoroidal; SR, subretinal; ST, superotemporal; vg, viral
genomes.
www.moleculartherapy.orgtransduction near the injection site, with GFP expression visible in
some retinal nerve ﬁber projections to the optic disc suggesting trans-
duction of retinal ganglion neurons (Figures 2B and 2E). In contrast,
intravitreal injection of the same dose of AAV8 showed only scant
peripapillary expression mostly nasal to the optic disc (Figures 2C
and 2F). Thus, without requiring vitrectomy surgery, transscleral mi-Molecularcroneedle injections allow both subretinal and suprachoroidal AAV
delivery with distinct patterns of transduction, and they are more efﬁ-
cient than intravitreal injections of AAV8.
When comparing cross-sectional retinal morphology in vivo
using SD-OCT, which correlates well with anatomic layers onTherapy: Methods & Clinical Development Vol. 16 March 2020 181
Figure 2. In Vivo GFP Transgene Expression after Suprachoroidal, Subretinal, and Intravitreal Injections of AAV8 in Rhesus Macaques
(A–C) Scanning laser ophthalmoscopy (SLO) montages and (D–F) magnified views of the red-dashed boxes in (A)–(C) showing different patterns of GFP expression
after suprachoroidal (A and D), subretinal (B and E), and intravitreal (C and F) AAV injections. (G–I) Spectral domain-optical coherence tomography (SD-OCT) scans
across the green dashed lines in (D)–(F), with (J–L) magnified views of the blue-dashed boxes in (G)–(I), showing impact on external limiting membrane (ELM),
photoreceptor inner segment/outer segment junction (IS/OS), and retinal pigment epithelium (RPE) after suprachoroidal (G and J), subretinal (H and K), and intravitreal
(I and L) AAV injections. ELM and IS/OS disruptions were seen in areas of greatest GFP transduction (open arrowheads) compared with adjacent areas with less
transduction (closed arrowheads). Scale bars, 1 mm (A–F), 0.2 mm (G–L). ELM, external limiting membrane; IS/OS, inner segment/outer segment junction; RPE, retinal
pigment epithelium.
Molecular Therapy: Methods & Clinical Developmenthistology,45,49 we found that outer retinal layers, including photo-
receptor inner segment/outer segment (IS/OS) junctions and
external limiting membrane (ELM), appear disrupted in areas of
highest GFP expression after suprachoroidal (Figures 2G and 2J)
and subretinal (Figures 2H and 2K) injections, as compared to in-
travitreal AAV8 (Figures 2I and 2K). We note, however, that
comparing retinal anatomy between these different modes of
AAV injection may be difﬁcult due to intrinsic differences in
retinal morphology at the different locations of GFP expression
(e.g., retinal layers are thinner and outer retinal bands are more
difﬁcult to discern on SD-OCT in peripheral retina as compared
to posterior regions).182 Molecular Therapy: Methods & Clinical Development Vol. 16 MarchRetinal Cell Tropism and Anatomy after Suprachoroidal or
Subretinal AAV8 Delivery
Histological analysis at 1 month conﬁrmed the widespread GFP
expression resulting from suprachoroidal AAV8 delivery (Figure 3A),
compared to the more focal expression after subretinal AAV (Fig-
ure 3B) and scant expression after intravitreal AAV (Figure 3C)
injections. The expression after suprachoroidal AAV8 was mostly
in individual RPE cells (Figures 3D and 3G), corresponding to the
punctate GFP ﬂuorescence pattern in vivo. However, the RPE cells
appear rounded and dysmorphic, with widespread disruption of
photoreceptor inner and outer segments (Figures 3G and 3J). In
contrast, subretinal AAV8 injection using transscleral microneedles2020
Figure 3. Retinal Cellular Tropism after Suprachoroidal, Subretinal, and Intravitreal Injection of AAV8 in Rhesus Macaques
(A–C) Epifluorescence image montages of entire globes showing different patterns of GFP transgene expression, and (D–F) confocal fluorescence images with (G–I)
magnified views of the white-dashed boxes in (D)–(F) showing GFP transgene expression (green) co-immunostained with anti-RPE65 (red) to label retinal pigment epithelium
(RPE), or (J–L) with peanut agglutinin (PNA, white) to label cone photoreceptor inner and outer segments, alongwith DAPI (blue) to label cell nuclei in eyes after suprachoroidal
(A, D, G, and J), subretinal (B, E, H, and K), and intravitreal (C, F, I, and L) injections of AAV8-CMV-GFP. Scale bars, 100 mm.
www.moleculartherapy.orgefﬁciently transduced RPE, photoreceptors, and some retinal gan-
glion neurons, with better preservation of retinal anatomy (Figures
3E and 3H). Most of the transduced photoreceptors appear to beMolecularrods, based on cell morphology, preponderance of rods in the trans-
duced area, and absence of co-staining with peanut agglutinin (PNA)
(Figures 3K), which is consistent with past studies showing mostlyTherapy: Methods & Clinical Development Vol. 16 March 2020 183
Figure 4. Transient GFP Expression in Retina and Choroid after Suprachoroidal AAV8 Delivery in Rhesus Macaques
(A–C) Confocal fluorescence images with (D–F) magnified views of the white-dashed boxes in (A)–(C) showing GFP transgene expression in the retinal pigment epithelium
(RPE) and sclera (green) co-immunostained with anti-RPE65 (red) to label RPE and with DAPI (blue) to label cell nuclei in eyes at 1 month (A and D), 2 months (B and E), and
3 months (C and F) after suprachoroidal (SC) injection of AAV8-GFP. Scale bars, 100 mm.
Molecular Therapy: Methods & Clinical Developmentrod transduction with standard transretinal subretinal AAV8 injec-
tions.46 Intravitreal AAV8 showed only GFP expression in cells in
the peripapillary region (Figures 3F, 3I, and 3L), with some colocali-
zation with some glial ﬁbrillary acidic protein (GFAP)+ cells, which
may include astrocytes or Müller glia based on their morphology
and distribution. Photoreceptor and RPE morphologies were also
more disorganized in regions closer to the injection site for both
transscleral suprachoroidal and subretinal injections (Figure S1).
Consistent with the in vivo imaging data, GFP expression after supra-
choroidal AAV8 injection was no longer present by months 2 and 3
(Figures 4A–4F), although GFP expression could still be detected in
the sclera near the injection site (Figures 4A–4C), suggesting that
the CMV promoter and expression cassette were still functional at
these time points, and that the GFP+ RPE cells were no longer present.
While it is unclear if the GFP+ cells in the sclera represent AAV-
transduced cells or phagocytes containing cellular debris with the
ﬂuorescent protein, the absence of co-immunostaining with ionized
calcium-binding adaptor-1 (Iba1), CD45, or GFAP in these regions
supports the former alternative.
Ocular Inflammatory Responses after Different Modes of AAV8
Delivery
Both subretinal and suprachoroidal AAV8 injections using trans-
scleral microneedles were well tolerated. There was no signiﬁcant184 Molecular Therapy: Methods & Clinical Development Vol. 16 Marchanterior chamber (AC) inﬂammation seen on slit lamp examination
(Figure S2). Rhesus 02 exhibited behavioral signs of ocular irritation
at week 2, was found to showmild AC cell (2+ based on the Standard-
ization of Uveitis Nomenclature [SUN] criteria50), and was treated
with oral prednisone (1 mg/kg) for 2 weeks with resolution of the
inﬂammation by the month 1 examination. Subsequent animals
were given a single 40-mg periorbital subtenon injection of triamcin-
olone and did not exhibit signiﬁcant AC inﬂammation after injections
(Table S1). None of the injected eyes exhibited signiﬁcant intraocular
pressure (IOP) elevation during the entirety of the study (Table S1),
and funduscopic examination and photographs showed no visible vit-
reous haze in any eye throughout the study (Figure S3).
On histological analysis, suprachoroidal AAV8 delivery caused signif-
icant inﬂammatory inﬁltration with Iba1+ cells in the outer retina and
choroid (Figure 5A), likely representing a mix of retinal microglia and
choroidal macrophages due to the disrupted RPE that normally con-
stitutes the outer BRB. In contrast, transscleral subretinal AAV8 and
intravitreal AAV8 showedminimal microglial activation compared to
an uninjected control eye (Figures 5B–5D). Suprachoroidal AAV8
also triggered more profound CD45+ leukocyte and CD3+ T cell inﬁl-
tration than did subretinal AAV8 (Figures 5E, 5F, 5I, and 5J), while
almost none was seen after intravitreal AAV8 or in uninjected eyes
(Figures 5G, 5H, 5K, and 5L), although the different inﬂammatory
reactions may be related to the different location and patterns of2020
Figure 5. Local Inflammatory Response after Suprachoroidal, Subretinal, and Intravitreal Injection of AAV8 in Rhesus Macaques
(A–P) Confocal fluorescence images of GFP transgene expression (green) co-immunostained with anti-IBA-1 (red) to label retinal microglia and choroidal macrophages (A–D),
anti-CD45 (red) to label infiltrating leukocytes (E–H), anti-CD3 (red) to label T cells (I–L), and anti-GFAP (red) to assess glial proliferation (M–P), in eyes that received
suprachoroidal (A, E, I, andM), subretinal (B, F, J, and N), and intravitreal (C, G, K, andO) injections of AAV8-CMV-GFP, or uninjected control eyes (D, H, L, and P). Scale bars,
100 mm.
www.moleculartherapy.orgtransgene expression. GFAP staining showed some reactive gliosis
with disruption of Müller glia after suprachoroidal and subretinal
AAV8 injections (Figures 5M–5P). Thus, suprachoroidal delivery of
AAV vectors appears to trigger chorioretinitis with localized inﬁltra-
tion of inﬂammatory cells in the retina and choroid.
Humoral Immune Responses after Different Modes of AAV8
Delivery
Because the suprachoroidal space is outside the outer BRB, we
evaluated whether AAV8 delivery to this compartment would elicitMoleculara greater systemic immune response than intravitreal AAV8 injec-
tions. Interestingly, animals that received suprachoroidal AAV8
using transscleral microneedles showed a less prominent NAb
response that began at 1 week and remained stable up to 3 months
(Figures 6A and 6C). In contrast, the animal that received intravi-
treal AAV8 demonstrated a more signiﬁcant elevation in NAb
titers at 1 month (Figures 6B and 6C), consistent with the response
to intravitreal AAV8 in previous primate studies.33,34 As predicted,
the animal that received the lower dose of AAV8 in both eyes
(7  1011 vg/eye) exhibited a milder NAb response. NAbs wereTherapy: Methods & Clinical Development Vol. 16 March 2020 185
Figure 6. Host Humoral Immune Responses after Suprachoroidal or Intravitreal AAV8 Injections in Rhesus Macaques
(A and B) Epifluorescence images of HEK293T cells incubated with macaque serum and AAV8-CMV-GFP to detect serum neutralizing antibodies (NAbs) before and after
suprachoroidal (SC/SC) (A) or intravitreal (IVT/IVT) (B) AAV8 injections. (C and D) Line graphs comparing serum (C) and aqueous (D) NAb titers in each study animal after AAV8
injections. The AAV8 injection mode and dose are labeled in (C). IVT, intravitreal; SC, suprachoroidal; SR, subretinal.
Molecular Therapy: Methods & Clinical Developmentnot detectable in aqueous samples of any study animals (Fig-
ure 6D). This corresponds to Goldmann-Witmer (G-W) ratio
below 4 in all eyes, which indicates minimal intraocular inﬂamma-
tion as detected from the aqueous after all modes of AAV injection
in our study. Since past studies did not show a signiﬁcant NAb
response after subretinal AAV8 alone,33,34 and because the animals
that received suprachoroidal and subretinal injection in fellow eyes
(rhesus 03 and rhesus 04) showed a similar NAb response as ani-
mals that received bilateral suprachoroidal injections, the humoral
immune response in these animals likely arose primarily from the
suprachoroidal AAV8.
DISCUSSION
Current gene therapy approaches often employ subretinal injection of
AAV vectors to allow direct access to photoreceptors and RPE for
effective gene transfer, and to exploit the relative immune privilege
of the subretinal space to minimize ocular inﬂammation. However,
subretinal injections are usually performed through the retina (trans-
retinally), requiring vitrectomy surgery and an operating microscope
for visualization. The procedure is invasive, costly, and difﬁcult to
repeat frequently, and the area of gene transfer using current tech-
niques may be localized to a small region near the injection site. Intra-
vitreal injections are easier to perform, but conventional AAV sero-
types have limited access to the outer retina due to the ILM
barrier,26 and they may trigger more vitreous inﬂammation and
host humoral immune responses.31,32186 Molecular Therapy: Methods & Clinical Development Vol. 16 MarchOur study demonstrates a novel mode of transscleral viral vector de-
livery that can be performed in an ofﬁce setting without surgery. By
injecting the AAV through the scleral wall to the subretinal or supra-
choroidal space, the technique provides more robust transgene
expression than do intravitreal injections and different patterns of
expression that may be suitable for different gene therapy applica-
tions. Similar to transretinal injections, transscleral microneedle in-
jections into the subretinal space produce focal gene transfer to
various cell types, including photoreceptors and RPE, with some
retinal ganglion cells near the injection site that may have resulted
frommechanical penetration of the microneedle into the inner retina.
By avoiding vitrectomy surgery or the need to create a retinotomy,
however, transscleral injections are easier to perform and less inva-
sive, with reduced risks of iatrogenic retinal tears, retinal detachment,
or other potential complications of vitreoretinal surgery. Unlike sub-
retinal injections, suprachoroidal AAV delivery provides diffuse,
widespread expression in peripheral RPE. The circumferential GFP
expression pattern reﬂects the anatomy of the choroidal-scleral junc-
tion, which is more readily separated in the periphery than in the pos-
terior pole. Histological studies have shown that the suprachoroid in
the macula appears more as a transition zone between the loose
collagen ﬁbers of the choroid stroma and the more compact architec-
ture of the sclera,36 which is why pathologic suprachoroidal effusions
tend to occur in the peripheral fundus. Hence, ﬂuid injected into the
suprachoroidal space may have a greater tendency to distribute cir-
cumferentially along the periphery rather than posteriorly toward2020
www.moleculartherapy.orgthe macula.35,38 In this way, suprachoroidal AAV delivery may be
better suited for gene therapies that target peripheral or RPE diseases,
or aimed at “biofactory” approaches such as the production of
anti-angiogenesis agents for neovascular retinal conditions, rather
than macular diseases or photoreceptor degenerations. Nevertheless,
further optimization of suprachoroidal injection location, volume,
or technique may improve delivery to the macular region. In this
study, we chose AAV8 due to its similarity to AAV2, which has
been widely used in clinical testing, and past studies demonstrating
their greater efﬁcacy in transducing photoreceptors and RPE as
well as reduced immunogenicity when given subretinally in
nonhuman primates.46,51 Further testing of additional AAV sero-
types, or methods to identify novel variants such as in vivo-directed
evolution,29 could help improve photoreceptor transduction from
these transscleral approaches.
In our study, we found that in vivo transgene expression after supra-
choroidal AAV8 delivery was transient, reaching maximal expression
at 1 month but decreasing by months 2 and 3. The persistent expres-
sion in scleral cells at these latter time points suggests that the CMV
promoter and transgene cassette remain active. Instead, the loss of
expression over time may have resulted from cellular damage and
phagocytic activity related to the local inﬁltration of inﬂammatory
cells and disruption of RPE and photoreceptor segments, which ap-
peared as early as 1 month after injection. Interestingly, while this
localized chorioretinitis was not as apparent after subretinal or intra-
vitreal delivery, we found that intravitreal AAV triggered more serum
NAbs than did subretinal or suprachoroidal AAV. The distinct im-
mune proﬁles with more localized inﬂammation after suprachoroidal
AAV and greater systemic humoral immune response after intravi-
treal AAV help elucidate the immune consequences of AAV exposure
to different compartments surrounding the outer BRB.
The BRB is composed of an inner barrier formed by endothelial tight
junctions of retinal capillaries and an outer barrier of tight junctions
in the RPE cell layer. Together, they provide a physical barrier that
contributes in part to the immune-privileged status of the retina
and subretinal space. Suprachoroidal injections expose AAV to resi-
dent macrophages in the choroid that likely function in immunosur-
veillance and pathogen detection of the extravascular milieu external
to the outer BRB. This is evident from the preponderance of Iba1+
cells, which, in the setting of signiﬁcant RPE disruption, may include
both choroidal macrophages and retinal microglia. At the same time,
the extremely high blood ﬂow through choroidal vessels—the highest
of any tissue in the body52—likely limits the systemic exposure of viral
vectors in the suprachoroidal space. In contrast, intravitreal AAVs
exhibit greater biodistribution in systemic circulation akin to intrave-
nous or intramuscular injections,32 and they are associated with
greater humoral and possibly cellular immune responses.31,33,53
This is likely due to the greater trabecular outﬂow of AAV from the
vitreous compared to the less efﬁcient uveoscleral outﬂow through
which suprachoroidal AAV could exit the eye. Hence, although
AAV sequestration in the suprachoroidal space may lead to greater
local inﬂammation, the higher systemic exposure of intravitrealMolecularAAV triggers a stronger systemic immune response, which may
reduce the efﬁcacy and durability of transgene expression.54 Never-
theless, additional studies are necessary to address the local inﬂam-
mation associated with suprachoroidal AAV delivery, as the distinct
immune response compared with intravitreal AAV may warrant
the use of local periocular or intraocular steroids rather than systemic
immunosuppression. Newer AAV variants may also trigger a reduced
immune response51 and could result in less local inﬂammation if
given suprachoroidally.
A previous study suggested the feasibility of delivering AAV5 to the
suprachoroidal space using an illuminated microcatheter in rabbit
eyes.55 However, the blood supply to the rabbit retina is merangiotic,
while humans and other primates have holangiotic retinal vascula-
ture. A more recent study by Ding et al.56 also demonstrated this
approach in Norway brown rats, but the ocular dimensions of the
rat eye are much smaller than humans and primates, and the supra-
choroidal space is more difﬁcult to access reliably. The team also
employed a conventional 27-gauge needle to deliver AAV8 supra-
choroidally in three nonhuman primates,56 but this free-hand tech-
nique is less precise and cannot exclude the possibility of inadvertent
subretinal delivery. In contrast, our study employed rhesus macaques
with ocular dimensions and vasculature similar to humans, and trans-
scleral microneedles, which reliably access the suprachoroidal space
with well-characterized biodistribution,57,58 and are already em-
ployed in human patients in phase I/II clinical trials.42,59 We also
employed in vivo SLO imaging, demonstrating the striking, unique
expression pattern of suprachoroidal AAV8, consistent with the
anatomic characteristics of the choroidal-scleral junction, which dif-
fers from subretinal or intravitreal AAV8 delivery.
In summary, we demonstrated a novel mode of AAV delivery using
transscleral microneedles to access the subretinal or suprachoroidal
space without the need for vitrectomy, retinotomy, or any surgical
maneuvers. Suprachoroidal injections of AAV8 provide widespread,
peripheral transgene expression in RPE, while subretinal AAV8
produces focal transduction of RPE and photoreceptors similar to
conventional transretinal techniques. Although suprachoroidal
AAV8 resulted in localized inﬂammation, the systemic humoral
immune response was less pronounced than with intravitreal deliv-
ery. Our study intentionally avoided extensive immunosuppression
in order to elucidate the native immune response to suprachoroidal
AAV delivery. Thus, future studies evaluating additional AAV vari-
ants or employing local or systemic immunosuppression may unveil
the true potential of this innovative approach.
MATERIALS AND METHODS
AAV8 Construct and Production
The AAV cis construct, which contained a CMV promoter, enhanced
GFP transgene, woodchuck hepatitis virus post-transcriptional regula-
tory element (WPRE), and bovine growth hormone (bGH) polyadeny-
lation signal, was packaged into AAV8 capsid and puriﬁed by the UC
Davis NEI Vision Molecular Construct and Packaging Core according
to the procedures described in Flannery and Visel.60 Vector titer wasTherapy: Methods & Clinical Development Vol. 16 March 2020 187
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SDS-PAGE. The nonhuman primate-grade AAV8 was prepared using
all endotoxin-free reagents. A single batch of AAV8 vectors was gener-
ated for this study, titered at 7.2  1013 vg/mL, stored in aliquots at
80C, and thawed as needed for all experiments in this study to avoid
freeze-thawing or potential variations in viral titer.
Ophthalmic Examinations and Study Schedule
Rhesus macaques selected for this study underwent ophthalmic exam-
ination at all time points. Ophthalmic imaging and aqueous ﬂuid and
serum collections were performed prior to AAV injections, and at
1 week, 1 month, and at the time of necropsy between 1 and 3 months.
For examinations and procedures, animals were sedated with intra-
muscular injection of ketamine hydrochloride, midazolam, and dex-
medetomidine, followed by pupillary dilation with phenylephrine
(Paragon Biotech), tropicamide (Bausch & Lomb), and cyclopentolate
(Akorn). Ophthalmic evaluations were conducted by portable slit lamp
biomicroscopy (SL-7E, Topcon) of the anterior segment, and by indi-
rect ophthalmoscopy (Heine) of the posterior pole. Anterior chamber
inﬂammation was graded from portable slit lamp examination using
SUN criteria for AC cells.50 Vitreous inﬂammation was graded from
indirect ophthalmoscopy using the National Eye Institute (NEI) scale
reported by Nussenblatt et al.61 for quantifying vitreous haze. IOP was
measured by rebound tonometry (TonoVet, Icare). External photo-
graphs of the anterior segment were captured using a digital camera
(Rebel T3, Canon). At study endpoint, a gross necropsy was performed
to examine body surfaces, oriﬁces, and cavities including heart, lungs,
liver, stomach, kidney, spleen, pancreas, gonads, and brain. Eyes were
collected in 4% paraformaldehyde immediately after euthanasia.
Intraocular Injections
After animal sedation, eyes were sterilely prepped with 1% povidone-
iodine and ﬂushed with sterile saline, followed by placement of an
eyelid speculum. For transscleral microneedle injections, a 700 mm-
long 30-gauge microneedle (Figure 1B, Clearside Biomedical) was in-
serted through the conjunctiva and sclera at 4 or 10 mm posterior to
the corneal limbus to inject into the superotemporal quadrant (single
100-mL injection) of left eyes and into both the superotemporal and
inferonasal quadrants (two 50-mL injections) of right eyes. For intra-
vitreal injections, a 0.5-inch-long 30-gauge needle (BD Biosciences)
was inserted through the pars plana, 4 mm posterior to the limbus,
in the inferotemporal quadrant (single 100-mL injection) of both
eyes. Anterior chamber taps were performed before and at all time
points following AAV delivery to remove 150 mL of aqueous ﬂuid us-
ing a 30-gauge needle for NAb testing. IOP was measured following
intraocular injections, and additional aqueous was removed if neces-
sary until the IOP was normalized. In rhesus 04, 05, and 06, a 40-mg
periorbital subtenon injection of triamcinolone acetonide suspension
(Kenalog-40, Bristol-Myers Squibb) was also performed in the super-
otemporal quadrant.
Ocular Imaging
All animals underwent SLO and SD-OCT using the Spectralis HRA+
OCT device (Heidelberg Engineering) before and at 1 week, 1 month,188 Molecular Therapy: Methods & Clinical Development Vol. 16 Marchand 2 or 3 months after AAV injections. Confocal SLO was used to
capture 55  55 or 30  30 ﬂuorescence images using 488-nm
excitation light and a long-pass barrier ﬁlter starting at 500 nm. Images
were captured from the central macula and from the peripheral retina
by manually steering the Spectralis device. Due to the facial contour of
these animals, the superior quadrants are more difﬁcult to visualize.
SD-OCT was performed alongside infrared reﬂectance images using
an 820-nm diode laser to capture 30  5 SD-OCT raster scans
with 1,536 A-scans per B-scan and 234 mm spacing between B-scans,
in high-resolution mode. SD-OCT scans were captured from the cen-
tral macula and in regions of visible GFP ﬂuorescence, especially near
the junction between transduced and untransduced tissues. 25 scans
were averaged for each B-scan using the Heidelberg Engineering eye
tracking automatic real-time (ART) software. Animals also underwent
color fundus photography (CF-1, Canon) for documentation of clinical
examination ﬁndings when possible.
Histology and Immunohistochemistry
Eyes were enucleated and placed in 4% paraformaldehyde (PFA) for
less than 30 min, followed by gentle removal of anterior segments,
including lens and vitreous. Whole eye cups were ﬁxed in 4% PFA
for 2 h at room temperature, rinsed with phosphate-buffered saline
(PBS), cryoprotected with 30% sucrose overnight, embedded in
optimal cutting temperature (OCT) medium, and then cryosectioned
(18 mm) using a cryostat (CM3050 S, Leica). For immunohistochem-
istry, sectionswere washedwith PBS, blockedwith 10% normal donkey
serum for 30 min, then incubated in primary antibody for 1–2 h
at room temperature, followed by Alexa Fluor 568-conjugated second-
ary antibodies (Invitrogen). Primary antibodies include RPE65
(MAB5428, 1:250, Millipore), EGFP (Novousbio, NB100-1770,
1:500), IBA-1 (Wako, AB10558, 1:100), GFAP (Dako, Z0334, 1:200),
CD45 (BD, 552566, 2.5 mg/mL), and CD3 (Abcam, ab11089, 1:100).
NAb Assays
NAb assays were performed on macaque sera or aqueous using an
AAV transduction inhibition assay as previously described.62 Brieﬂy,
96-well plates were coated with poly-L-lysine (0.1 mg/mL), and
HEK239T cells were seeded at 1 105 per well with DMEM contain-
ing 10% fetal bovine serum (FBS) at 37Cwith 5%CO2. The following
day, cells were exposed to human adenovirus type 5 (VR-1516,
ATCC) at an MOI of 90 for 2 h to increase susceptibility to AAV8.
Aqueous or macaque sera were serially diluted from 1:5 to 1:2,560,
mixed with AAV8-CMV-GFP virus at an MOI of 50,000, and then
co-incubated at 37C for 1 h. The serum-virus or aqueous-virus com-
plexes were then incubated with the HEK293T cells for 48 h, and
GFP+ cells were detected with an inverted ﬂuorescence microscope
(Eclipse, Nikon). G-W ratios were calculated as the ratio of the
aqueous NAb titer to the serum NAb titer.
Study Approval
The California National Primate Research Center (CNPRC) is ac-
credited by the Association for Assessment and Accreditation of Lab-
oratory Animal Care (AAALAC) International. All studies using rhe-
sus macaques (Macaca mulatta) followed the guidelines of the2020
www.moleculartherapy.orgAssociation for Research in Vision and Ophthalmology (ARVO)
Statement for the Use of Animals in Ophthalmic and Vision Research
and complied with the National Institutes of Health (NIH) Guide for
the Care and Use of Laboratory Animals. All procedures were con-
ducted under protocols approved by the Institutional Animal Care
and Use Committee (IACUC, protocol #20341).
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